Literature DB >> 26014951

Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii.

Gabriella Freitas Ferreira1, Julliana Ribeiro Alves Santos2, Marliete Carvalho da Costa2, Rodrigo Assunção de Holanda2, Ângelo Márcio Leite Denadai3, Gustavo José Cota de Freitas2, Áquila Rodrigues Costa Santos4, Priscila Batista Tavares4, Tatiane Alves Paixão2, Daniel Assis Santos5.   

Abstract

Cryptococcus gattii is the main etiological agent of cryptococcosis in immunocompetent individuals. The triazole drug itraconazole is one of the antifungals used to treat patients with cryptococcosis. Heteroresistance is an adaptive mechanism to counteract the stress of increasing drug concentrations, and it can enhance the ability of a microorganism to survive under antifungal pressure. In this study, we evaluated the ability of 11 C. gattii strains to develop itraconazole heteroresistance. Heteroresistant clones were analyzed for drug susceptibility, alterations in cell diameter, capsule properties, and virulence in a murine model. Heteroresistance to itraconazole was intrinsic in all of the strains analyzed, reduced both the capsule size and the cell diameter, induced molecular heterogeneity at the chromosomal level, changed the negatively charged cells, reduced ergosterol content, and improved the antioxidant system. A positive correlation between surface/volume ratio of original cells and the level of heteroresistance to itraconazole (LHI) was observed in addition to a negative correlation between capsule size of heteroresistant clones and LHI. Moreover, heteroresistance to itraconazole increased the engulfment of C. gattii by macrophages and augmented fungal proliferation inside these cells, which probably accounted for the reduced survival of the mice infected with the heteroresistant clones and the higher fungal burden in lungs and brain. Our results indicate that heteroresistance to itraconazole is intrinsic and increases the virulence of C. gattii. This phenomenon may represent an additional mechanism that contributes to relapses of cryptococcosis in patients during itraconazole therapy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26014951      PMCID: PMC4505268          DOI: 10.1128/AAC.00466-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis.

Authors:  Asna A Siddiqui; Annemarie E Brouwer; Vannaporn Wuthiekanun; Shabbar Jaffar; Robin Shattock; Diane Irving; Joanna Sheldon; Wirongrong Chierakul; Sharon Peacock; Nicholas Day; Nicholas J White; Thomas S Harrison
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

2.  Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.

Authors:  Julliana Ribeiro Alves Santos; Ludmila Ferreira Gouveia; Erika Linzi Silva Taylor; Maria Aparecida Resende-Stoianoff; Gerson Antônio Pianetti; Isabela Costa César; Daniel Assis Santos
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

3.  Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier.

Authors:  Caroline Charlier; Fabrice Chrétien; Marielle Baudrimont; Elodie Mordelet; Olivier Lortholary; Françoise Dromer
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 4.  The Cryptococcus neoformans capsule: a sword and a shield.

Authors:  Teresa R O'Meara; J Andrew Alspaugh
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

5.  Itraconazole therapy for cryptococcal meningitis and cryptococcosis.

Authors:  D W Denning; R M Tucker; L H Hanson; J R Hamilton; D A Stevens
Journal:  Arch Intern Med       Date:  1989-10

6.  Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.

Authors:  Edward Sionov; Hyeseung Lee; Yun C Chang; Kyung J Kwon-Chung
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

7.  Ultrastructural study of Cryptococcus neoformans by quick-freezing and deep-etching method.

Authors:  N Sakaguchi; T Baba; M Fukuzawa; S Ohno
Journal:  Mycopathologia       Date:  1993-03       Impact factor: 2.574

Review 8.  Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection.

Authors:  Brendan Joseph McMullan; Tania Christine Sorrell; Sharon Chih-Ann Chen
Journal:  Future Microbiol       Date:  2013-12       Impact factor: 3.165

9.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

10.  Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans.

Authors:  Alexandre Alanio; Marie Desnos-Ollivier; Françoise Dromer
Journal:  MBio       Date:  2011-08-09       Impact factor: 7.867

View more
  14 in total

1.  Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.

Authors:  Rafael Wesley Bastos; Hellem Cristina Silva Carneiro; Lorena Vívien Neves Oliveira; Karen Maia Rocha; Gustavo José Cota Freitas; Marliete Carvalho Costa; Thaís Furtado Ferreira Magalhães; Vanessa Silva Dutra Carvalho; Cláudia Emanuela Rocha; Gabriella Freitas Ferreira; Tatiane Alves Paixão; Frédérique Moyrand; Guilhem Janbon; Daniel Assis Santos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Eugenol Induces Phenotypic Alterations and Increases the Oxidative Burst in Cryptococcus.

Authors:  Júnia C O Alves; Gabriella F Ferreira; Julliana R Santos; Luís C N Silva; João F S Rodrigues; Wallace R N Neto; Emmanueli I Farah; Áquila R C Santos; Brenda S Mendes; Lourimar V N F Sousa; Andrea S Monteiro; Vera L Dos Santos; Daniel A Santos; Andrea C Perez; Thiago R L Romero; Ângelo M L Denadai; Luciana S Guzzo
Journal:  Front Microbiol       Date:  2017-12-07       Impact factor: 5.640

3.  Treatment with pCramoll Alone and in Combination with Fluconazole Provides Therapeutic Benefits in C. gattii Infected Mice.

Authors:  Jannyson J Jandú; Marliete C Costa; Julliana R A Santos; Fernanda M Andrade; Thais F Magalhães; Márcia V Silva; Maria C A B Castro; Luanna C B B Coelho; Aline G Gomes; Tatiane A Paixão; Daniel A Santos; Maria T S Correia
Journal:  Front Cell Infect Microbiol       Date:  2017-05-24       Impact factor: 5.293

4.  High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.

Authors:  Julliana Ribeiro Alves Santos; Noelly Queiroz Ribeiro; Rafael Wesley Bastos; Rodrigo Assunção Holanda; Letícia Chagas Silva; Estela Rezende Queiroz; Daniel Assis Santos
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

5.  In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant Enterobacteriaceae.

Authors:  Tania Cebrero-Cangueiro; Rocío Álvarez-Marín; Gema Labrador-Herrera; Younes Smani; Elisa Cordero-Matía; Jerónimo Pachón; María Eugenia Pachón-Ibáñez
Journal:  Front Cell Infect Microbiol       Date:  2018-10-18       Impact factor: 5.293

6.  Evaluation of the interaction between polymyxin B and Pseudomonas aeruginosa biofilm and planktonic cells: reactive oxygen species induction and zeta potential.

Authors:  Marlucy Rodrigues Lima; Gabriella Freitas Ferreira; Wallace Ribeiro Nunes Neto; Joveliane de Melo Monteiro; Áquila Rodrigues Costa Santos; Priscila Batista Tavares; Ângelo Márcio Leite Denadai; Maria Rosa Quaresma Bomfim; Vera Lúcia Dos Santos; Sirlei Garcia Marques; Andrea de Souza Monteiro
Journal:  BMC Microbiol       Date:  2019-05-29       Impact factor: 3.605

Review 7.  Ecoepidemiology of Cryptococcus gattii in Developing Countries.

Authors:  Patricia F Herkert; Ferry Hagen; Rosangela L Pinheiro; Marisol D Muro; Jacques F Meis; Flávio Queiroz-Telles
Journal:  J Fungi (Basel)       Date:  2017-11-03

Review 8.  The status of cryptococcosis in Latin America.

Authors:  Carolina Firacative; Jairo Lizarazo; María Teresa Illnait-Zaragozí; Elizabeth Castañeda
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-04-05       Impact factor: 2.743

9.  A phenylthiazole derivative demonstrates efficacy on treatment of the cryptococcosis & candidiasis in animal models.

Authors:  Nívea P Sá; Caroline M Lima; Julliana R A Dos Santos; Marliete C Costa; Patrícia P de Barros; Juliana C Junqueira; Jéssica A Vaz; Renata B Oliveira; Beth B Fuchs; Eleftherios Mylonakis; Carlos A Rosa; Daniel A Santos; Susana Johann
Journal:  Future Sci OA       Date:  2018-04-25

10.  Influenza A Virus as a Predisposing Factor for Cryptococcosis.

Authors:  Lorena V N Oliveira; Marliete C Costa; Thaís F F Magalhães; Rafael W Bastos; Patrícia C Santos; Hellem C S Carneiro; Noelly Q Ribeiro; Gabriella F Ferreira; Lucas S Ribeiro; Ana P F Gonçalves; Caio T Fagundes; Marcelo A Pascoal-Xavier; Julianne T Djordjevic; Tania C Sorrell; Daniele G Souza; Alexandre M V Machado; Daniel A Santos
Journal:  Front Cell Infect Microbiol       Date:  2017-09-26       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.